繁體
  • 简体中文
  • 繁體中文

熱門資訊> 正文

Needham Raises Price Target on RxSight to $66 From $54, Adds Stock to Conviction List, Keeps Buy Rating

2024-08-20 19:20

07:20 AM EDT, 08/20/2024 (MT Newswires) -- RxSight (RXST) has an average investment rating of buy among analysts polled by Capital IQ, with price targets ranging from $54 to $75.

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www.mtnewswires.com/contact-us)

風險及免責提示:以上內容僅代表作者的個人立場和觀點,不代表華盛的任何立場,華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前,應結合自身情況,考慮投資產品的風險。必要時,請諮詢專業投資顧問的意見。華盛不提供任何投資建議,對此亦不做任何承諾和保證。